Phase 3 RCT in limited-stage small cell lung cancer: adding concurrent and adjuvant atezolizumab to chemoradiation did not improve overall survival (median 31.1 vs 36.1 months; HR 1.03) or progression-free survival.
RCT
Higgins et al. Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005